Scientists at the University of Washington presented at the annual meeting of the Endocrine Society (ENDO-2019) a report on the success of first phase study on male contraception. Detailed report was also published in the scientific journal JCEM.
According to researchers, forty men took part in the pill experiment, ten of whom gave a placebo under the guise of medicine. The rest received two dosage options for the drug: 200 and 400 mg. All participants were required to take one capsule daily during the meal. The experiment took place within 28 days.
During the course of an experimental medication codenamed 11-beta-MNTDC, scientists have noted a significant decrease in the level of luteinizing and follicle-stimulating hormones among volunteers. However, as noted in the report, the main objective of the study was to find a safe drug for health indicators, and not to check its effectiveness.
